Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer

Anti-Cancer Drugs

Volumn 11, Issue 9, 2000, Pages 681-685

  Schwonzen, M ^a   Kurbacher, C M ^b   Mallmann, P ^b  

^a St Walburga Krankenhaus   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Liposomal doxorubicin; Metastatic breast cancer; Paclitaxel

Indexed keywords

DOXORUBICIN; EPIRUBICIN; LIPOSOME; MITOXANTRONE; PACLITAXEL;

ADULT; AGED; ALOPECIA; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENCAPSULATION; FEMALE; HUMAN; LEUKOPENIA; METASTASIS; MUCOSA INFLAMMATION; NEUROPATHY; PRIORITY JOURNAL; SKIN TOXICITY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LIPOSOMES; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; PILOT PROJECTS; POLYETHYLENE GLYCOLS;

EID: 0033670039     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200010000-00002     Document Type: Article

References (20)

1. Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic
2. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
3. Eastern cooperative oncology group studies of paclitaxel and doxorubicin in advanced breast cancer
4. Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: An Eastern Cooperative Oncology Group study
5. Is there a place for 'dose-dense' weekly schedules of the taxoids?
6. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: Laboratory study and clinical pilot trial
7. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/ cyclophosphamide in patients with metastatic breast cancer: The French experience
8. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer
9. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation
10. Pharmacological, toxicological, and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes
11. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy
12. Liposomal doxorubicin (Dox-SLTM): Antitumor activity and unique toxicities during two complementary phase I studies
13. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
14. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial
15. Efficacy and safety of stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma
16. Liposomal-entrapped doxorubicin: An active agent in AIDS-related Kaposi's sarcoma
17. Caelyx ® (Doxil®; liposomal doxorubicin) is tolerated well longterm at high cumulative dose in AIDS-related Kaposi's sarcoma (AIDS-KS) patients - A meta-analysis of 1716 patients
18. Liposomal doxorubicin for treatment of AIDS-related Kaposi's sarcoma
19. Reporting results of cancer treatment
20. Decreased cardiac toxicity by TLC D-99 (liposome encapsulated doxorubicin) vs. Doxorubicin in a randomized trial of metastatic breast carcinoma (mbc)